7 results about "Daunorubicina" patented technology

This invention provides an Auger electron radiotherapy drug that can selectively and effectively release a sufficient amount of Auger electrons into the nuclear DNA of cancer cells, even in small amounts, thereby reducing or killing cancer cells. The Auger electron radioactive isotope has a half-life that is not too short but not too long, making it highly safe and readily available. [Solution] The Auger electron radioactive therapeutic agent is encapsulated in a stimulus-responsive liposome that accumulates in cancer tissue and / or cancer cells, such that an anthracycline derivative is released upon stimulation, in which an Auger electron-emitting radioisotope-substituted benzene ring-containing group or radioisotope-substituted alkyl group is covalently bonded to the keto or amino group of anthracyclines selected from doxorubicin or daunorubicin and their reduced forms or alkoxy group-substituted forms thereof, is a stimulus-responsive liposome, or is bound to an antibody, oligopeptide, or antigen that accumulates in cancer tissue and / or cancer cells via a stimulus-responsive linker.

The invention discloses application of brutinib and a combined pharmaceutical composition thereof in treatment of leukemia, and the leukemia comprises acute myelogenous leukemia, chronic myelogenous leukemia, T acute lymphoblastic leukemia and B acute lymphoblastic leukemia. The invention creatively finds that the brutinib has a remarkable synergistic effect on treatment of the leukemia when being combined with the vinca, the cytarabine or the daunorubicin for use, and a brand new drug combination scheme provided by the invention provides a more effective drug combination choice for treatment of the leukemia, and is expected to improve the treatment effect of patients with the leukemia.

(3R, 4S)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H- chromen-7-ol (TRX-E-002-1) for use in a method of treatment for a hematological cancer being acute myeloid leukemia or multiple myeloma in a subject in need thereof, the method comprising administering to the subject an effective amount of TRX-E-002-1. The method may further comprise administering to the subject an effective amount of a second compound selected from the group consisting of (i) a BCL-2 inhibitor such as venetoclax, navitoclax or obatoclax, (ii) a deoxycytidine analogue chemotherapeutic such as cytarabine or gemcitabine, (iii) a hypomethylating agent such as azacitidine or decitabine, (iv) an anthracycline chemotherapeutic such as daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin or mitoxantrone, (v) a proteasome inhibitor such as carfilzomib, bortezomib, and ixazomib, (vi) an immunomodulatory drug such as pomalidomide, lenalidomide, and thalidomide and(vii) a corticosteroid drug such as dexamethasone or prednisone, and (viii) an alkylator such as bendamustine, cyclophosphamide, melphalan, and melflufen. Corresponding combination pharmaceutical compositions.

The invention provides a method for improving the efficiency of preparing daunorubicin by fermenting streptomyces coeruleorubidus, which is used for improving the expression quantity of dnrK gene in streptomyces coeruleorubidus. The invention also provides a streptomyces coeruleorubidus genetic engineering strain, which is obtained by replacing an endogenous promoter at the upstream of a methyltransferase / decarboxylase coding gene dnrK with a promoter with a sequence of SEQ ID NO: 3. According to the invention, the strong promoter is utilized to over-express the methyltransferase / decarboxylase coding gene dnrK, the streptomyces coeruleorubidus strain is modified, the yield of daunorubicin of the dnrK over-expressed engineering bacteria is increased by 46%, and technical support is provided for increasing the yield of daunorubicin in industrial production.

The invention relates to compositions and methods for treating patients with hematological proliferative disorders with CPX-351, a liposomal composition of daunorubicin and cytarabine, and venetoclax.

The application provides an exosome composition for reducing side effects of chemotherapy treatment and a preparation method thereof, and belongs to the technical field of medicines. Methotrexate, vinblastine and daunorubicin are prepared into a co-crystal, loaded on UiO-66-NH2 connected with RGD, loaded on exosomes, and embedded in an acrylic acid, traditional Chinese medicine polysaccharide and pullulan compound to obtain a sustained-release high half-life exosome system, which is uniformly mixed with D-ribose, yeast-beta glucan and glutathione to obtain the exosome composition for reducing side effects of chemotherapy treatment. The traditional Chinese medicine polysaccharide is traditional Chinese medicine polysaccharide obtained by boiling water extraction and ethanol precipitation of radix codonopsis, angelica, polygonatum sibiricum and dendrobium officinale. The exosome composition for reducing side effects of chemotherapy treatment is prepared, drug resistance of tumor cells is reduced, drug efficacy is improved, side reactions after chemotherapy are reduced, the effect of targeted slow release of drugs is achieved, and the exosome composition has a wide application prospect.

The present invention relates to a novel prodrug of the disulfide of aldonolactone reductase inhibitor II based on its formula I (systematic name "disulfalane"), to a method of preparing the disulfide of formula I, to the use of the disulfide of formula I for inhibiting the aldonolactone reductases AKR1B1 and AKR1B10, to the use of the disulfide of formula I in the prevention or treatment of diseases in which the activity of the aldonolactone reductases AKR1B1 and AKR1B10 is a key cause of the formation and development of said diseases, to the use of the disulfide of formula I for the prevention or treatment of cancers derived from chronic inflammation, i.e. colon cancer, lung cancer, breast cancer, liver cancer, prostate cancer, pancreatic cancer, endometrial cancer and cervical cancer. The present invention also relates to the use of the disulfide of formula I as an adjuvant therapy drug in combination with clinically used chemotherapeutic drugs, which can also be substrates of aldonolactone reductases, such as doxorubicin and daunorubicin, for the treatment of cancer. The disulfide of formula I is not active as an inhibitor of the aldonolactone reductases AKR1B1 and AKR1B10 itself, but after oral or parenteral administration it is metabolized in the body, preferably in cancer cells characterized by an increased reducing potential due to a significantly increased GSH content compared to healthy cells, thus producing two molecules of semimestar of formula II, i.e. an inhibitor of the activity of aldonolactone reductases. The disulfide of formula I according to the present invention can also have the advantage that it is better absorbed in the acidic environment of the tumor compared to semimestar of formula II alone. The disulfide of formula I can be used alone or in a pharmaceutically acceptable form: mono- or di-salt, mono- or di-ester, amide or combinations thereof or other agents, optionally in combination with other anti-inflammatory or anticancer therapeutic drugs.(I)